drugset / Trial / NCT00437294

Enzastaurin in Combination of Capecitabine to Treat Breast Cancer

NCT00437294

Phase 2 Terminated 86 enrolled Eli Lilly and Company
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine whether the combination of enzastaurin and capecitabine is more effective than the combination of placebo and capecitabine in treating participants with breast cancer who were previously treated with an anthracycline and a taxane.

Timeline

Start
2007-03
Primary completion
2009-03
Completion
2009-03

Drugs

EvaluationDrugModalityDoseRoute
Subject enzastaurin Small molecule 500 mg Oral
Background Capecitabine Small molecule 1250 mg/m2

Indications